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Introduction {#Sec2}
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Stock and Downs first defined airway pressure release ventilation (APRV) as maintenance of a continuous positive airway pressure (CPAP) that allows for spontaneous breaths without significant airway pressure fluctuation and a brief cyclic release phase for efficient ventilation (i.e., CPAP with release) \[[@CR1]\]. However, the flexibility of this definition has become an Achilles heel of sorts since a wide variety of APRV settings have all been used in the literature making comparison between studies impossible. Therefore, the current acronym "APRV" is a nebulous term identifying a ventilator mode without a precisely defined mechanical breath structure or ventilator settings. Variability in settings, and thus mechanical breath structure, significantly changes how the lung "sees" the breath being delivered. The first description of APRV published by Stock et al. in 1987 was, "APRV is a new way to administer simultaneously a supportive level of CPAP and assist CO~2~ elimination" \[[@CR2]\]. Thus, the original definition of APRV was simply CPAP with a release to eliminate CO~2~. CPAP with a release is a very general description of a mechanical breath and can define all of the mechanical breaths seen in Fig. [1](#Fig1){ref-type="fig"}. Indeed, all of these mechanical breaths were defined as APRV \[[@CR2]--[@CR5]\]. As can be readily seen, the biggest difference between these APRV breaths is the duration at inspiration and expiration. Since the original definition of APRV was CPAP with a release, which did not specify the duration of the CPAP or release time, all of these breaths fit the original definition. Over the 30 years since APRV was originally described, many combinations of CPAP and release times have been used and all defined as APRV.Fig. 1Comparison of APRV pressure waveforms. Artistic depiction of airway pressure waveforms, all of which were defined as APRV, illustrating the significant variability in what has been defined as an APRV breath. Stock in 1987 used 60 % CPAP with T~Low~ of 1.27 s and a respiratory rate (RR) of 20 \[[@CR2]\]. Davis in 1993 used a similar %CPAP, but decreased the RR by prolonging T~High~ and T~Low~ \[[@CR3]\]. Gama de Abreau in 2010 simulated conventional ventilation with a prolonged T~Low~ and short T~High~ \[[@CR4]\]. Finally, Roy in 2013 used a very brief adaptive T~Low~ and large T~High~ with 90 % CPAP \[[@CR5]\]. Of note, though the ventilator pressure is set at zero, this does not reflect true pressure as the brief T~Low~ prevents full deflation of the lung, and thus prevents end-expiratory pressure from reaching zero. Figures **a**--**c** are examples of fixed-APRV (F-APRV) and figure **d** of personalized APRV (P-APRV)

In this review, we examine published original research in both animal and human trials in which the authors stated they utilized APRV, or a comparable but differently named ventilator mode. Our goals with this review were as follows: (1) to examine the historical evolution of APRV methodology; (2) to evaluate the efficacy of the APRV methodologies versus conventional positive pressure ventilation (CPPV); and (3) to determine if there are optimal APRV settings for maximal lung protection.

The evolution of APRV mostly revolves around modifying the CPAP and release time durations (time at expiration---T~Low~) (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"}, %CPAP and T~Low~). However, the most significant evolution in APRV has been the development of the ability to personalize the expiratory duration to precisely meet the needs of the patient's changing lung physiology. The advantage of this method is that expiratory duration is set to maintain and open and stable the lung, regardless the level of lung pathology. Since there was no consistency in the CPAP and release time duration in the published literature, we chose to separate APRV strategies into two categories: fixed- (F-APRV) and personalized (P-APRV) APRV. If the expiratory duration or release time was not adjusted by mechanical changes in the lung, regardless of duration of CPAP or release time, it was categorized as F-APRV. If the APRV strategy sets expiratory duration by changes in lung mechanics, using the slope of the expiratory flow curve, it was categorized as P-APRV (Fig. [1](#Fig1){ref-type="fig"}).Table 1Summary of animal studies utilizing F-APRVFirst authorYear*n*AnimalStudy design% CPAPT~Low~FindingsStock \[[@CR2]\]198710Mongrel dogCrossover\
CPPV vs. APRV58 %1.27 sAPRV improved oxygenation with lower PIP and without cardiopulmonary compromiseRasanen \[[@CR21]\]198810Mongrel dogCrossover\
CPPV vs. CPAP vs. APRV50 %1.5 sCPPV impaired circulatory function and tissue oxygen balance, APRV had higher systemic vascular resistance and decreased pulmonary vascular resistanceMartin \[[@CR17]\]19917Neonatal sheepCrossover\
Spont vs. CPAP vs. CPPV vs. APRV50 %1 sAPRV augmented alveolar ventilation vs. CPAP, and had lower Paw than PPV without compromised cardiovascular functionSmith \[[@CR23]\]19955SwineCrossover\
CPAP vs. APRV80 %1.1 s exp flow 0APRV maintains oxygenation without hemodynamic compromiseNeumann \[[@CR19]\]20019SwineCrossover\
CPAP vs. APRV +/− PEEP67 %1 sAPRV decreased O2 compared with CPAP, No difference with PEEPHering \[[@CR13]\]200312SwineCrossover\
APRV +/− SB50 %N/AAPRV + SB increased oxygenation and cardiovascular functionWrigge \[[@CR24]\]200324SwineRandomized prospective\
APRV +/− SB50 %1.5--2 sAPRV + SB increased oxygenation and cardiovascular functionNeumann \[[@CR20]\]200520SwineRandomized prospective\
APRV +/− SB50 %1.5 sAPRV + B increased ventilation in dependent lung and decreased shuntHering \[[@CR14]\]200512SwineCrossover\
APRV vs. SB50 %\~1.7 sAPRV + SB improved oxygenation after lung injuryWrigge \[[@CR25]\]200522SwineRandomized Prospective\
APRV +/− SB50 %1.5--2 sAPRV + SB redistributes ventilation to dependent lung regions and counters cyclic collapseHering \[[@CR12]\]200812SwineCrossover\
APRV +/− SB50 %N/AAPRV + SB improved oxygenation and splanchnic blood flowGama de Abreu \[[@CR9]\]200812SwineCrossover\
BiPAP + SB, PSV +/− sighs, "noisy" PSVN/Aexp flow 0"Noisy" CPPV improved oxygenation by redistributing perfusionCarvalho \[[@CR7]\]20095SwineCrossover\
PSV vs. BiPAP + SBTitrated by P~aw~N/ABiPAP + SB and pressure support had similar oxygenation improvement and did not improve aeration of dependent lungGama de Abreu \[[@CR4]\]201010SwineCrossover\
PSV vs. BiPAP + SB25 %N/ABiPAP + SB had lower tidal volume with comparable oxygenation and ventilation distributionHenzler \[[@CR11]\]201020SwineRandomized prospective\
APRV +/− SB42 %\~1.2 sElevated IAH impaired respiratory mechanics regardless of SBKreyer \[[@CR16]\]201012SwineRandomized Prospective\
APRV +/− SB50 %1.5--2 s\
exp flow 0APRV + SB improved systemic blood flow and cerebrospinal blood flowMatsuzawa \[[@CR18]\]201021RabbitRandomized prospective\
CPPV vs. LTV vs. APRV95 %0.15 sAPRV reduced HMGB1 levels and lung waterSlim \[[@CR22]\]20117SwineCase series\
APRV80 %N/AIncreased P~aw~ increased pulmonary capillary wedge pressure and left atrial pressure, but these may not correlate with end diastolic volumeXia \[[@CR26]\]201124RabbitRandomized prospective\
APRV +/− SB50 %N/AAPRV + SB improved oxygenation and attenuated VILICarvalho \[[@CR8]\]201436SwineRandomized prospective\
APRV +/− SB50 %N/AAPRV + SB improved oxygenation and reduced lung injuryGuldner \[[@CR10]\]201412SwineCrossover\
APRV +/− SB50 %\~1 sHigher levels of SB reduce global lung stress and strain with minimal changes in perfusionKill \[[@CR15]\]201424SwineRandomized prospective\
CPPV vs. Bilevel vs. Compression synchronized ventilation40 %3.6 sCPPV and Bilevel usable during CPR, though compression synchronized ventilation was bestNumber of studies: 22*T* ~*Low*~ time at low pressure, *CPPV* conventional positive pressure ventilation, *LTV* low tidal volume ventilation, *CPAP* continuous positive airway pressure, *SB* spontaneous breathing, *PEEP* positive end-expiratory pressure, *PIP* peak inspiratory pressure, *P* ~*aw*~ airway pressure, *PSV* pressure support ventilation, *BiPAP* biphasic positive airway pressureTable 2Summary of animal studies utilizing P-APRVFirst authorYear*n*AnimalStudy design%CPAPT~Low~FindingsAlbert \[[@CR49]\]201122SwineRandomized prospective, CPPV vs. LTV vs. APRV vs. HFOV90 %50--75 % PEFAPRV increased oxygenation and ventilation with reduced cytokines compared to LTVRoy \[[@CR57]\]20128SwineRandomized prospective, CPPV vs. APRV90 %75 % PEFEarly APRV prevented ARDS with improved oxygenation, histopathology, and surfactant protein preservationEmr \[[@CR62]\]201316RatRandomized prospective, spont vs. CPPV vs. APRV90 %75 % PEFEarly APRV prevented ARDS with improved oxygenation and histopathologyRoy \[[@CR5]\]201312SwineRandomized prospective, sham vs. LTV vs. APRV90 %75 % PEFEarly APRV prevented ARDS with improved oxygenation and histopathology with reduced inflammatory markersRoy \[[@CR61]\]20139RatRandomized prospective, CPPV vs. APRV90 %75 % PEFEarly APRV prevented ARDS with improved oxygenation and histopathologyKollisch-Singule \[[@CR55]\]20148RatRandomized prospective, CPPV vs. APRV90 %10 or 75 % PEFAPRV with low expiratory time reduced conducting airway microstrainKollisch-Singule \[[@CR54]\]20146RatRandomized prospective, CPPV with PEEP vs. APRV90 %10 or 75 % PEFAPRV with low expiratory time reduced alveolar microstrainDavies \[[@CR52]\]201522SwineRandomized prospective, LTV vs. APRV90 %75 % PEFAPRV increased oxygenation compared with LTV, APRV had a "trend towards" increased cerebral ischemia.Arrindell \[[@CR51]\]201519Preterm swineRandomized prospective, CPPV vs. APRVN/A75 % PEFAPRV increased oxygenation without change in histopathology or inflammatory markersKollisch-Singule \[[@CR56]\]201514RatRandomized prospective, uninjured vs. LTV vs. APRV90 %75 % PEFAPRV approximated control lungs best with increased homogeneity compared to LTV. LTV with high PEEP reduced heterogeneity.Number of studies: 10*T* ~*Low*~ time at low pressure, *CPPV* conventional positive pressure ventilation, *LTV* low tidal volume ventilation, *CPAP* continuous positive airway pressure, *PEF* peak expiratory flow, *SB* spontaneous breathing, *PEEP* positive end-expiratory pressure, *PIP* peak inspiratory pressureTable 3Summary of human trials using F-APRVFirst authorYear*n*Study design%CPAPT~Low~FindingsGarner \[[@CR31]\]198814Crossover\
CPPV baseline with APRV weanN/A1.5 sAPRV maintained similar oxygenation with \>50 % reduced PIPRasanen \[[@CR40]\]199150Crossover\
PEEP titrated CPPV vs. APRV50 %1.5 sAPRV maintained similar oxygenation with \>50 % reduced PIPCane \[[@CR28]\]199118Crossover\
CPPV vs. APRV67 %1.5 sAPRV maintained similar oxygenation and cardiopulmonary function with reduced PIPDavis \[[@CR3]\]199315Crossover\
CPPV vs. APRV32 %2.6 ± 0.6APRV maintained similar oxygenation with \>50 % reduced PIP and reduced PEEPChiang \[[@CR29]\]199418Crossover\
CPPV vs. APRV66 %1.5 sAPRV maintained similar oxygenation with \>50 % reduced PIPSydow \[[@CR42]\]199418Crossover\
CPPV vs. APRV80 %0.5--0.7APRV maintained similar oxygenation with decreased A-a gradient after 8 h and reduced PIPBratzke \[[@CR27]\]199820Crossover\
CPPV vs. APRV88 %1APRV maintained similar oxygenation with reduced PIPKaplan \[[@CR36]\]200112Crossover\
Inverse ratio PPV vs. APRV85 %0.8APRV is safe, decreases PIP and need for sedation/paralytics/pressors, increases CIPutensen \[[@CR39]\]200130Randomized prospective\
CPPV vs. APRVIdentical to CPPVExp flow 0APRV + SB maintained increased oxygenation, CI, and pulmonary compliance with reduced ALI/ARDS incidence and sedative requirementsSchultz \[[@CR41]\]200115Crossover\
CPPV vs. APRVN/AN/AAPRV maintained similar oxygenation with \>50 % reduced PIPWrigge \[[@CR45]\]200114Randomized prospective\
APRV +/− automatic tube compensationN/AN/AAPRV with tube compensation increased end-expiratory lung volume and minute ventilation without affecting oxygenation or cardiopulmonary statusHering \[[@CR34]\]200212Crossover\
APRV +/− SBN/AN/AAPRV + SB had increased renal blood flow and glomerular filtration rateVarpula \[[@CR43]\]200333Randomized prospective\
CPPV vs. APRVN/AExp flow 0APRV feasible in prone positioning and increased oxygenation at 24 hVarpula \[[@CR44]\]200458Randomized prospective\
CPPV vs. APRV80 %1APRV had similar mortality and ventilator free daysDart \[[@CR30]\]200546Crossover\
CPPV vs. APRVN/A40--50 % PEFAPRV reduced PIP and increased oxygenationLiu \[[@CR37]\]200958Retrospective case-control\
CPPV vs. APRV67 %\~1.5APRV reduced pressor use/A-a gradient and increased oxygenationKamath \[[@CR35]\]201011Retrospective cohort\
CPPV vs. APRV70 %1.2 ± 0.9APRV had no adverse effects on blood pressure or urine outputGonzalez \[[@CR32]\]2010468Case matched retrospective\
CPPV vs. APRV70 %N/AAPRV maintained similar oxygenation with reduced PIP and associated increased tracheostomy rateMaxwell \[[@CR38]\]201063Randomized prospective\
LTV vs. APRVN/A25--75 % PEFAPRV had similar physiological parameters despite increased disease severity at baselineHanna \[[@CR33]\]201145Retrospective case series\
CPPV vs. APRVN/AN/AAPRV had increased P/F Ratio, lung procurement rate with similar graft survival rateMaung \[[@CR46]\]201238Retrospective case series\
APRV85 %0.8--1Switching from CPPV to APRV improved oxygenation and decreased PCO~2~ without hemodynamic compromiseMaung \[[@CR47]\]2012362Retrospective case series\
CPPV vs. APRVN/AN/AAPRV had increased ventilator days.Testerman \[[@CR48]\]201348Case-matched retrospective\
APRV; obese vs. nonobeseN/AN/AAPRV in morbidly obese similar to nonobese, though morbidly obese required extended care after discharge more oftenNumber of studies: 23*T* ~*Low*~ time at low pressure, *CPPV* conventional positive pressure ventilation, *LTV* low tidal volume ventilation, *CPAP* continuous positive airway pressure, *PEF* peak expiratory flow, *SB* spontaneous breathing, *PEEP* positive end-expiratory pressure, *PIP* peak inspiratory pressureTable 4Summary of human trial utilizing P-APRVFirst authorYear*n*Study design%CPAPT~Low~FindingsYoshida \[[@CR60]\]200918Retrospective case-control\
LTV vs. APRVN/A50--75 % PEFAPRV + SB had increased oxygenation and MAP and decreased atelectasisWalsh \[[@CR58]\]201120Retrospective case series\
CPPV vs. APRV\>80 %50--75 % PEFAPRV improved pulmonary blood flow after tetralogy of fallot repair or cavopulmonary shuntAndrews \[[@CR50]\]201366,099Retrospective review\
CPPV vs. early APRV90 %75 % PEFEarly APRV decreased ARDS incidence tenfold and mortality threefoldKawaguchi \[[@CR53]\]201413Retrospective case series\
CPPV vs. APRV90 %50--75 % PEFAPRV safe in pediatric ARDS without hemodynamic compromiseYehya \[[@CR59]\]2014104Retrospective cohort\
HFOV vs. APRVN/A50--75 % PEFAPRV had no mortality effect compared to oscillatory ventilation as rescue treatmentsNumber of studies: 5*T* ~*Low*~ time at low pressure, *CPPV* conventional positive pressure ventilation, *LTV* low tidal volume ventilation, *PEF* peak expiratory flow, *SB* spontaneous breathing

Methodology {#Sec3}
-----------

A PubMed search of the terms "Airway Pressure Release Ventilation", "APRV", "Bi-Vent", "APRV/Biphasic" and "Bi-Level" and "Mechanical Ventilation" OR "Ventilator" was conducted alone or in combination. English language studies between the years 1987 and 2015 were included, and studies testing non-invasive ventilator strategies alone, reviews, editorials, and case studies were excluded, yielding 52 articles. Of the 60 articles, 32 were animal studies and 28 human studies (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"}). APRV methodologies were analyzed by examining the following settings: (1) pressure during inspiration/CPAP phase (P~High~); (2) time during inspiration/CPAP phase (T~High~); (3) pressure during expiration/release phase (P~Low~); (4) time during expiration/release phase (T~Low~); and (5) percent CPAP (%CPAP) to reflect the time spent at P~High~ relative to the entire breath duration $\documentclass[12pt]{minimal}
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                \begin{document}$$ \left(\frac{T_{\mathrm{High}}}{T_{\mathrm{High}}+{T}_{\mathrm{Low}}}\times \kern0.5em 100\right) $$\end{document}$. In addition, we assessed the factors used to titrate these settings including respiratory rate or partial pressure of carbon dioxide (PCO~2~) for T~High~ and T~Low~ and oxygenation or plateau pressure for P~High~.

Reviewing the evolution of APRV from its inception in 1987, we noted a major paradigm shift in the way APRV is set. Initially, the variations in settings were to the inspiratory and expiratory duration time that were fixed and not adjusted to changes in lung mechanics (Fig. [1a](#Fig1){ref-type="fig"}--[c](#Fig1){ref-type="fig"}). In 2005, Habashi published a paper with a novel method of setting the expiratory duration based on changing lung mechanics identified by the slope of the expiratory flow curve (Figs. [1d](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}) \[[@CR6]\]. This novel method of setting expiratory duration sets this personalized APRV (P-APRV) strategy (Figs. [1d](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}) apart from all other fixed setting-APRV (F-APRV) strategies.Fig. 2Method of setting expiratory duration (T~Low~). **a** Typical personalized airway pressure release ventilation (P-APRV) airway pressure and flow curves. Correctly set P-APRV has a very brief release phase (time at low pressure---T~Low~) and CPAP phase (time at high pressure---T~High~) \[[@CR6]\]. The T~High~ is \~90 % of each breath. The two other P-ARPV settings are the pressure at inspiration (P~High~) and at expiration (P~Low~). T~Low~ is sufficiently brief such that end-expiratory pressure (P~Low~) never reaches 0 cmH~2~O measured by the tracheal pressure (*green line*). **b** Maintain alveolar stability by adaptively adjusting the expiratory duration as directed by the expiratory flow curve. The rate of lung collapse is seen in the normal (slope 45°) and acutely injured lung (ARDS, slope 30°). ARDS causes a more rapid lung collapse due to decreased lung compliance. Our preliminary studies have shown that if the end-expiratory flow (EEF; −45 L/min) to the peak expiratory flow (PEF; −60 L/min) ratio is equal to 0.75, the resultant T~Low~ (0.5 s) is sufficient to stabilize alveoli \[[@CR54], [@CR55]\]. The lung with ARDS collapses more rapidly such that the EEF/PEF ratio of 75 % identifies an expiratory duration of 0.45 s as necessary to stabilize alveoli. Thus, this method of setting expiratory duration is adaptive to changes in lung pathophysiology and personalizes the mechanical breath to each individual patient

Thus, we chose to divide our review of APRV efficacy into these two basic categories. The F-APRV breath with a relatively short inspiratory time (T~High~) occupying \<90 % of total cycle time (Fig. [1a](#Fig1){ref-type="fig"}--[c](#Fig1){ref-type="fig"}) of each breath with a fixed expiratory time (T~Low~) that is not adjusted based on changing lung mechanics. The second category originally described by Habashi \[[@CR6]\] was a P-APRV breath with the following settings: (1) the inspiratory pressure (P~High~) is set to the desired plateau pressure,; (2) the T~High~ is typically set to occupy 90 % of the total cycle time of each breath (Fig. [2a](#Fig2){ref-type="fig"}); (3) the T~Low~ set based on changes in lung mechanics by analyzing the slope of the expiratory flow curve (Fig. [2b](#Fig2){ref-type="fig"}); and (4) the expiratory pressure (P~Low~) is set at 0 cmH~2~O to minimize resistance to convective expiratory gas flow and maximize ventilation. The short duration at end expiration prevents the airway pressure from reaching atmospheric pressure, thus maintaining a positive end-expiratory pressure. Based on the above criteria, the studies reviewed were placed into either the F-APRV (Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}) or P-APRV (Tables [2](#Tab2){ref-type="table"} and [4](#Tab4){ref-type="table"}) category.

Results {#Sec4}
-------

Animal (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}) and human (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}) studies were examined for APRV settings and efficacy. As described above, the APRV methodologies were subdivided into two categories: F-APRV; (Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}) and P-APRV (Tables [2](#Tab2){ref-type="table"} and [4](#Tab4){ref-type="table"}). The majority of the animal studies (69 % of total) \[[@CR2], [@CR4], [@CR7]--[@CR26]\] and human studies (82 % of total) \[[@CR3], [@CR27]--[@CR48]\] were in the F-APRV category.

### How expiratory duration was personalized {#Sec5}

The expiratory flow curve is analyzed, and the ratio of the end-expiratory flow (EEF) to the peak expiratory flow (PEF) is set so that the EEF/PEF ratio is 75 % \[[@CR5], [@CR49]--[@CR62]\] (Fig. [2b](#Fig2){ref-type="fig"}) based on the methodology described by Habashi \[[@CR6]\] (Tables [2](#Tab2){ref-type="table"} and [4](#Tab4){ref-type="table"}). The T~Low~ is thus personalized based on alterations in lung mechanics, identified by changes in the slope of the expiratory flow curve (Fig. [2b](#Fig2){ref-type="fig"}). Using EEF/PEF ratio of 75 % results in a brief T~Low~ ranging from 0.3 to 0.6 s (Fig. [1d](#Fig1){ref-type="fig"}). However, recent animal experiments have shown the optimal EEF/PEF ratio necessary to open and stabilize the lung is 75 % \[[@CR54]--[@CR56]\].

### F-APRV: inspiratory duration {#Sec6}

There was considerable variability in the F-APRV settings (i.e., duration at inspiration and expiration) in the papers reviewed, and in multiple papers, the settings were not defined, and thus not included in this review. Swine, dogs, and rabbits were used in the animals studies with the majority of studies using swine (Table [1](#Tab1){ref-type="table"}). In only two of the animal studies were the %CPAP set at ≤80 % of the total cycle time (Table [1](#Tab1){ref-type="table"}) \[[@CR22], [@CR23]\]. In one study, %CPAP was set very short at 25 % of the breath cycle time \[[@CR5]\]. When both the animal and human studies were analyzed 23/45 studies set %CPAP ≤67 % of the breath and 13/45 had an indeterminate %CPAP (Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}).

### Expiratory duration {#Sec7}

In addition, the T~Low~ in both animal and human studies was prolonged to levels seen in conventional mechanical ventilation (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR3], [@CR9], [@CR15], [@CR16], [@CR24], [@CR25], [@CR43]\]. Aside from two studies \[[@CR30], [@CR38]\], the T~Low~ remained fixed or was titrated based on the PCO~2~ as opposed to being adjusted based on changes in lung mechanics using the expiratory flow curve (Fig. [2](#Fig2){ref-type="fig"}). The P~High~ was titrated very differently in the studies reviewed, with a range between 10 cmH~2~O \[[@CR2], [@CR21], [@CR28], [@CR29], [@CR31]\] and 35 cmH~2~O \[[@CR3], [@CR37]\] depending on whether the target was maximal oxygenation, maximal lung recruitment, or a specific tidal volume. In addition, most of the studies in the F-APRV group set a positive P~Low~ \> 0 cmH~2~O \[[@CR2], [@CR4], [@CR7]--[@CR11], [@CR13], [@CR14], [@CR16], [@CR18]--[@CR23], [@CR26], [@CR40]\].

### Outcome {#Sec8}

The majority of the studies in the F-APRV group were crossover experiments, representing 59 % of the animal studies (Table [1](#Tab1){ref-type="table"}) and 48 % of the human trials (Table [3](#Tab3){ref-type="table"}) \[[@CR2], [@CR4], [@CR7], [@CR9], [@CR10], [@CR12]--[@CR14], [@CR17], [@CR19], [@CR21], [@CR23], [@CR32]\], with the primary goal to demonstrate that APRV could be safely used without adverse effects on lung function or hemodynamic characteristics. Many crossover trials showed similar or increased oxygenation with lower peak pressures and no negative effect on hemodynamics with APRV as compared with CPPV \[[@CR2], [@CR3], [@CR17], [@CR27]--[@CR32], [@CR39]--[@CR42]\], and some studies showed hemodynamic improvement with APRV \[[@CR13], [@CR24], [@CR36], [@CR39]\]. Prospective randomized trials comparing APRV and CPPV showed that APRV is safe and potentially beneficial (Table [3](#Tab3){ref-type="table"}). In none of the studies included in this review did APRV cause a significant negative impact on the physiologic process being studied, and in some prospective randomized studies, APRV was shown beneficial (Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}).

### P-APRV {#Sec9}

Similar to the F-APRV studies, P-APRV either resulted in improved outcomes or no change as compared with CPPV and in none of the studies was APRV shown to be harmful. Unlike the F-APRV studies that were mainly crossover studies, all of the P-APRV animal studies were randomized prospective cohort trials that compare non-protective CPPV or low tidal volume (LTV) with APRV \[[@CR5], [@CR49], [@CR52], [@CR54], [@CR55], [@CR57], [@CR61], [@CR62]\]. P-APRV was shown to reduce heterogeneity and both alveolar and alveolar duct micro-strain (i.e., change in alveolar size with applied stress) \[[@CR54]--[@CR56]\] suggesting a mechanism for the improvement in the efficacy experiments (Table [3](#Tab3){ref-type="table"}) \[[@CR5], [@CR49], [@CR57], [@CR61], [@CR62]\].

Discussion {#Sec10}
----------

There has been no consensus on what parameters are essential to define a mechanical breath as being APRV, and thus, APRV settings have been inconsistent over the three decades since it was first described. However, no studies have shown that APRV is harmful or significantly inferior as compared with conventional mechanical ventilation. In 2005, Habashi clearly defined the settings for what we have termed personalized APRV or P-APRV \[[@CR6]\]. P-APRV has a prolonged T~High~ and very brief T~Low~ duration, which is set by lung mechanics using the change in the slope of the expiratory flow curve \[[@CR6]\]. Not only is the T~Low~ very brief in P-APRV, it is set by analyzing the slope of the expiratory flow curve and therefore adaptive to changes in the patient's lung mechanics (Fig. [2b](#Fig2){ref-type="fig"}). Using these precisely controlled APRV settings, a number of studies have shown that P-APRV recruits and stabilizes the alveoli and alveolar ducts \[[@CR54]--[@CR56]\] and reduces the incidence of ARDS in multiple animal models \[[@CR5], [@CR57], [@CR62]\]. A meta-analysis has shown a reduction in ARDS incidence in trauma patients \[[@CR53]\]. Given this lack of consensus on how APRV should be set, the remainder of the "[Discussion](#Sec10){ref-type="sec"}" will be divided into the results obtained from the F-APRV and P-APRV subgroups, rather than discuss the findings from each experiment with a different %CPAP, T~Low~, and/or P~High~ settings.

### F-APRV studies {#Sec11}

Since, as previously mentioned, most of the animal and human studies were crossover experiments (i.e., switching from CPPV or spontaneous breathing to F-APRV in the same animal or patient), the majority of published APRV studies do not address efficacy (i.e., is APRV superior to conventional ventilation). It is important to note that APRV did not cause a significant negative impact, as compared with CPPV or spontaneous breathing, on the physiologic parameters that were measured in any of the crossover studies (Table [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}). In the randomized prospective animal studies, F-APRV was shown to be beneficial. It was shown that APRV reduced lung water and HMGB1 in rabbits \[[@CR18]\], improved systemic and cerebrospinal blood flow in swine \[[@CR16]\], improved oxygenation and attenuated ventilator-induced lung injury (VILI) in rabbits \[[@CR26]\], and improved oxygenation and reduced lung injury in swine \[[@CR7]\].

In humans, Putsenen et al. showed that APRV with spontaneous breathing increased oxygenation, cardiac index, and pulmonary compliance, with reduced sedative requirements compared with CPPV in humans \[[@CR39]\]. Varpula et al. reported similar mortality and ventilator-free days for APRV and CPPV, and also demonstrated that it is feasible to utilize APRV with prone positioning. In that study, T~Low~ was set specifically to allow expiratory flow to reach zero, which would allow the lung to collapse during expiration \[[@CR43], [@CR44]\]. Maxwell et al. showed no difference between low tidal volume ventilation (LTV) and APRV regarding mortality, ventilator days, ICU length of stay, or complication rates despite increased baseline disease severity in the APRV group \[[@CR38]\]. In human retrospective trials, the APRV methodology used was not consistent among the studies analyzed (Table [3](#Tab3){ref-type="table"}). Despite these inconsistencies, Gonzalez et al. showed that APRV reduced peak inspiratory pressure (PIP) while maintaining similar oxygenation levels \[[@CR32]\]. Hanna et al. showed increased PaO~2~/FiO~2~ (P/F) ratio, lung procurement rate, and graft survival when used in organ donors where the lungs were transplanted \[[@CR33]\].

A retrospective study examining trauma patients by Maung et al. demonstrated increased ventilator days on APRV compared with an unspecified method of CPPV \[[@CR47]\]. However, this study excluded all mortality in the interest of investigating weaning and the baseline characteristics of the groups were different, with more severe chest trauma and decreased P/F ratio at the start in the APRV group. Further, this study used respiratory therapist-guided protocol weaning only in the CPPV group, whereas the APRV group had random, non-protocolized weaning based on physician guidance.

### P-APRV {#Sec12}

Despite defining the role of tidal volume (Vt) and plateau pressure on VILI in ARDS patients \[[@CR63]\], our current understanding of the parameters comprising the mechanical breath that either propagate or impede progressive acute lung injury (ALI) is incomplete. The mechanism of VILI is believed to be the evolution from a normal homogenously ventilated lung into a heterogeneously ventilated lung, with collapse and edema-filled alveoli adjacent to open alveoli. This heterogeneity results in stress concentrators and recurrent alveolar collapse and reopening with each tidal breath that amplify lung tissue injury, instigated by the initial insult such as sepsis, trauma, or pneumonia \[[@CR64]--[@CR66]\]. Thus, the ventilation strategy that restores or maintains homogeneity would minimize VILI and obstruct progressive ALI \[[@CR64], [@CR66], [@CR67]\].

P-APRV uses a 90 % CPAP phase that recruits alveoli resulting in homogeneous lung inflation (Fig. [2a](#Fig2){ref-type="fig"}) and a brief release phase with the T~Low~ personalized to the mechanics of the lung (Fig. [2b](#Fig2){ref-type="fig"}) producing a nearly static ventilated lung, which prevents alveolar collapse and reopening, thereby reducing dynamic tissue strain \[[@CR54], [@CR56]\]. The question is, do these APRV settings that stabilize alveoli protect the lung?

In prospective outcome animal experiments, P-APRV resulted in an increase in oxygenation along with a decrease in histopathologic injury as compared with CPPV and LTV ventilation strategies \[[@CR5], [@CR52], [@CR57], [@CR61], [@CR62]\]. Several studies showed that P-APRV resulted in an increase in surfactant protein concentration \[[@CR5], [@CR57], [@CR62]\], while two showed a reduction of inflammatory markers (Table [2](#Tab2){ref-type="table"}) \[[@CR49], [@CR57]\].

Kollisch-Singule et al. \[[@CR54]--[@CR56]\] conducted three micro-anatomic studies (i.e., alveoli and alveolar ducts) that demonstrated reduced alveolar and conducting airway micro-strain as well as increased alveolar homogeneity using P-APRV in which the T~Low~ was set to maintain an EEF/PEF ratio 75 or 10 %. The T~Low~ set using an EEF/PEF ratio of 75 % was sufficiently short to stabilize alveoli and prevent alveolar collapse, whereas extending the T~Low~ (EEF/PEF ratio 10 %) resulted in alveolar collapse and instability. These studies add mechanistic support to efficacy studies showing that preemptive P-APRV reduced ARDS incidence in a clinically applicable porcine ARDS model \[[@CR5], [@CR57]\].

Davies et al. \[[@CR52]\] showed increased oxygenation with P-APRV as compared with LTV, with no significant differences in cerebral ischemia in a swine model of concomitant brain and lung injury (Table [2](#Tab2){ref-type="table"}). In patients, Yoshida et al. \[[@CR60]\] demonstrated increased oxygenation and mean arterial pressure (MAP) with decreased atelectasis using P-APRV as compared to LTV ventilation. Walsh et al. \[[@CR58]\] showed improved pulmonary blood flow when using P-APRV versus CPPV ventilation post-operatively after tetratology of Fallot repair or cavopulmonary shunt in neonates (Table [4](#Tab4){ref-type="table"}).

Furthermore, Andrews et al. \[[@CR50]\] in a meta-analysis showed a tenfold decrease in ARDS incidence as well as a threefold decrease in mortality when compared to trauma patients with similar injuries that were treated with standard of care ventilation in 15 trauma intensive care units (Table [4](#Tab4){ref-type="table"}). However, all of the human trials testing the P-APRV method \[[@CR50], [@CR53], [@CR58]--[@CR60]\] are retrospective studies, and as such, it is not clear that the precise P-APRV settings were followed, aside from the study by Andrews et al. \[[@CR50]\] that strictly adhered to the P-APRV protocol throughout the study in trauma patients. Despite this, the human results are in concordance with multiple animal studies \[[@CR5], [@CR49], [@CR54]--[@CR57], [@CR61], [@CR62]\] that support the clinical data \[[@CR50]\] that P-APRV may be used to reduce the incidence of acute respiratory distress syndrome (ARDS) more effectively than conventional LTV ventilation applied early or after the onset of ARDS.

### A note on mechanical ventilators {#Sec13}

An often under-analyzed aspect of mechanical breath delivery is the ventilator used to deliver the breath. Every ventilator has a specific design with differing resistances built into the ventilator gas path, responses to spontaneous ventilation, as well as software quirks that affect breath delivery. APRV may be named in various ways based on the ventilator in use such as (1) APRV (Drӓger Evita, Savina and V series, Hamilton G5), (2) Bi-Vent (Maquet Servo-i), (3) BiLevel (Engström Carestation, Puritan Bennett 840 & 980), and (4) APRV/Biphasic (Viasys Avea). However, even more problematic than the different names is the wide variation in their implementation of APRV.

In particular, the ability to control key APRV parameters such as the T~Low~ varies, and fine control of this parameter is critical to properly set P-APRV (Fig. [2b](#Fig2){ref-type="fig"}). APRV strategies on some ventilators have deviated from the original concept of a timed CPAP with a release phase, by adding pressure support (PS). This requires a trigger that creates a need for synchronization with the ventilator resulting in automated changes to both the inspiratory and expiratory duration. More specifically, the T~Low~, which is critical to control end-expiratory lung volume and prevent airway closure, spontaneously adjusts when PS is added to this mode on these ventilators, regardless of the T~Low~ setting, producing large and variable tidal volumes leading to lung volume loss and alveolar instability. So, even if APRV was set accurately by the clinician, the ventilator may automatically adjust the duration of the release phase (T~Low~) ultimately allowing the lung to collapse. This effect would be similar to conventional ventilation automatically adjusting Vt or PEEP without physician input.

Furthermore, many researchers define APRV as "extreme" inverse-ratio pressure-control ventilation (IR-PCV). However, unlike IR-PCV, P-APRV does not set a defined I:E ratio. Rather, the CPAP phase is briefly interrupted by a "release phase" (i.e., T~Low~) that is established by independently setting a T~Low~ based upon analysis of the expiratory flow curve. Further, patients can breathe spontaneously throughout the entire respiratory cycle in APRV, superseding the set I:E ratio. Unfortunately, many times the exact make and model of the ventilator was not reported in the papers reviewed, and thus, we could not categorize studies by the ventilator used, but it is an important factor to consider if the ventilator being used can accurately deliver P-APRV.

### Current state of APRV and clinical implications {#Sec14}

As described previously, there is a paucity of data testing APRV with identical settings, especially in clinical trials almost all of which were retrospective or crossover studies. Rose et al. \[[@CR68]\] reviewed the literature in 2008 and concluded that there is a lack of consistency in APRV settings making comparison with conventional ventilator strategies difficult. Another recent review by Facchin et al. \[[@CR69]\] examined the current literature for both APRV and high-frequency oscillatory ventilation (HFOV) for treatment and prevention of ARDS; the authors concluded that there is inconsistent evidence and a lack of high quality trials to make conclusions regarding APRV or HFOV efficacy.

It is clear from the studies examined in this review that APRV has evolved from a mechanical breath defined as a prolonged CPAP phase with a brief release phase \[[@CR1]\] into a highly sophisticated, dynamic mechanical breath with precise settings that are responsive to changes in lung physiology (i.e., P-APRV) \[[@CR6]\]. Although the mechanical breath used by both Downs and Habashi are referred to as APRV, the actual mechanical breath created by each is very different (Fig. [1a](#Fig1){ref-type="fig"}, [d](#Fig1){ref-type="fig"}) \[[@CR2], [@CR57]\] as is the breath created and studied in other experiments \[[@CR3], [@CR9]\] (Fig. [1b](#Fig1){ref-type="fig"}, [c](#Fig1){ref-type="fig"}). The current use of the APRV acronym remains an imprecise term that demands a specific definition of parameter settings to be utilized consistently. Obviously, some APRV settings are going to superior to others in their ability to protect the lung.

P-APRV appears to be an exciting and novel open lung strategy that may significantly reduce ARDS incidence, morbidity, and mortality of established ARDS. Data suggests that rather than overdistending alveoli, the extended T~High~/P~High~ redistributes gas from the alveolar ducts to the alveoli, where it belongs \[[@CR54], [@CR55]\] and changes heterogeneous to homogeneous alveolar ventilation \[[@CR56]\]. The calculated strain on alveoli was significantly reduced demonstrating that mechanical stretch on the alveolar wall was decreased. These data have led us to conclude that the extended inspiratory duration has a powerful positive impact on reducing strain at the alveolar level. We hypothesize that the mechanism of this protection (i.e., reduce alveolar strain) is secondary to increased lung volume and the number of recruited alveoli. The extended T~High~ "nudges" open alveoli over a several hours in a non-pathologic manner resulting in open lung ventilation. Since the lung becomes fully recruited with significantly improved compliance, even with relatively high tidal volumes (10--14 cm^3^/kg), the driving pressure is not increased (unpublished observations).

Conclusions {#Sec15}
===========

Although many settings have been used, none of the studies reviewed showed a worse outcome using APRV as compared with CPPV, with many studies showing significant benefits in cardiopulmonary variables. The evolution of APRV methodology has been drastic from Downs and Stock (F-APRV) \[[@CR1]\] to the P-APRV method of Habashi \[[@CR6]\]. P-APRV allows for a personalized control of lung stability on a breath-to-breath basis that is not possible with other modes of ventilation. P-APRV is an adaptive, flow directed, duration dependent ventilation strategy that adapts the setting to each patient regardless of their lung pathophysiology. This personalized, adaptive mechanical breath may prove more efficacious at treating and preventing ARDS than the current standard of care. Ultimately, more studies are needed using consistent and well-defined settings to identify the optimal APRV breath necessary to maximize lung protection.

ALI

:   acute lung injury

APRV

:   airway pressure release ventilation

ARDS

:   acute respiratory distress syndrome

BiPAP

:   biphasic positive airway pressure

CPAP

:   continuous positive airway pressure

CPPV

:   conventional positive pressure ventilation

F-APRV

:   fixed-setting airway pressure release ventilation

HFOV

:   high frequency oscillatory ventilation

LTV

:   low tidal volume

MAP

:   mean arterial pressure

P/F
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P-APRV

:   personalized airway pressure release ventilation

P~aw~

:   airway pressure

PCO~2~

:   partial pressure of carbon dioxide

PEEP

:   positive end-expiratory pressure

PEF

:   peak expiratory flow

P~High~

:   pressure during CPAP phase

PIP

:   peak inspiratory pressure

P~Low~

:   pressure during release phase

PS

:   pressure support

PSV

:   pressure support ventilation
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:   spontaneous breathing

T~High~
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T~Low~

:   time at release/P~Low~

VILI

:   ventilator-induced lung injury

Vt
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